{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:52:18Z","timestamp":1791071538781,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-026-03211-y","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:29:40Z","timestamp":1791023380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; tovorafenib and dordaviprone for glioma, mirvetuximab soravtansine and pembrolizumab for ovarian cancer, tislelizumab for nasopharyngeal cancer, trastuzumab deruxtecan, palbociclib and datopotamab deruxtecan for breast cancer, epcoritamab for lymphoma, teclistamab for multiple myeloma"],"prefix":"10.1007","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"3211_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) List of approved drugs (in Japanese). https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html Accessed on 21 Sep 2026"},{"key":"3211_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang DA, Hansford JR et al (2024) The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 30:207\u2013217. https:\/\/doi.org\/10.1038\/s41591-023-02668-y","journal-title":"Nat Med"},{"key":"3211_CR3","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE et al (2023) Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med 389:2162\u20132174. https:\/\/doi.org\/10.1056\/NEJMoa2309169","journal-title":"N Engl J Med"},{"key":"3211_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","volume":"42","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany I, Gardner SL, Odia Y et al (2024) ONC201 (Dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J Clin Oncol 42:1542\u20131552. https:\/\/doi.org\/10.1200\/JCO.23.01134","journal-title":"J Clin Oncol"},{"key":"3211_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H et al (2023) Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 41:1061-1072.e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.014","journal-title":"Cancer Cell"},{"key":"3211_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, Jiang Z, Zhang Q et al (2026) Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med 394:551\u2013562. https:\/\/doi.org\/10.1056\/NEJMoa2508668","journal-title":"N Engl J Med"},{"key":"3211_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","volume":"407","author":"N Colombo","year":"2026","unstructured":"Colombo N, Zsiros E, Parma G et al (2026) Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet 407:1525\u20131537. https:\/\/doi.org\/10.1016\/S0140-6736(26)00602-1","journal-title":"Lancet"},{"key":"3211_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","volume":"407","author":"L Falchi","year":"2026","unstructured":"Falchi L, Nijland M, Huang H et al (2026) Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet 407:161\u2013173. https:\/\/doi.org\/10.1016\/S0140-6736(25)02360-8","journal-title":"Lancet"},{"key":"3211_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa2511218","volume":"394","author":"O Metzger","year":"2026","unstructured":"Metzger O, Mandrekar S, Goel S et al (2026) Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med 394:451\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2511218","journal-title":"N Engl J Med"},{"key":"3211_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","volume":"394","author":"LJ Costa","year":"2026","unstructured":"Costa LJ, Bahlis NJ, Perrot A et al (2026) Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med 394:739\u2013752. https:\/\/doi.org\/10.1056\/NEJMoa2514663","journal-title":"N Engl J Med"},{"key":"3211_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.annonc.2026.03.008","volume":"37","author":"R Dent","year":"2026","unstructured":"Dent R, Shao Z, Schmid P et al (2026) Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Ann Oncol 37:1066\u20131080. https:\/\/doi.org\/10.1016\/j.annonc.2026.03.008","journal-title":"Ann Oncol"},{"key":"3211_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency (2026) Revisions of PRECAUTIONS (FY2026). https:\/\/www.pmda.go.jp\/english\/safety\/info-services\/drugs\/revision-of-precautions\/0014.html Accessed on 21 Sep 2026"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03211-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:03:45Z","timestamp":1791068625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":12,"alternative-id":["3211"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03211-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"3 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}